SCHEMBL29324601

SCHEMBL29324601

CCN(CC)CCCc1ccccc1CC(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 3/20 0.49
CHRM1 P11229 3/20 0.49
CHRM2 P08172 3/20 0.49
SLC6A2 P23975 2/20 0.49
SLC6A4 P31645 2/20 0.49
ADRA1A P35348 2/20 0.49
OPRM1 P35372 2/20 0.49
DRD3 P35462 2/20 0.49
SLC6A3 Q01959 2/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
DRD1 P21728 1/20 0.49
SIGMAR1 Q99720 2/20 0.46
TSHR P16473 1/20 0.41
GABRA1 P14867 1/20 0.40
GABRB2 P47870 1/20 0.40
DRD2 P14416 1/20 0.39
ADRA2C P18825 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28065380 0.78 LIPG (0.52) GABRA1GABRB2
SCHEMBL9715937 0.77 GABRA1 (0.56) SLC6A2SLC6A4SLC6A3SIGMAR1GABRA1
SCHEMBL10987064 0.76 KCNH2 (0.62) KCNH2CHRM1CHRM2SLC6A2SLC6A4
SCHEMBL8128253 0.74 GABRA1 (0.45) SLC6A2SLC6A4SLC6A3SIGMAR1GABRA1
SCHEMBL840750 0.74 GABRA1 (0.64) SLC6A2SLC6A4SLC6A3SIGMAR1GABRA1
SCHEMBL23964428 0.73 GABRA1 (0.65) OPRM1DRD3HTR1ASIGMAR1TSHR
SCHEMBL8123791 0.73 GABRA1 (0.44) SIGMAR1GABRA1GABRB2
SCHEMBL5174943 0.72 GABRA1 (0.61) SLC6A2SLC6A4SLC6A3SIGMAR1GABRA1
SCHEMBL5174936 0.72 GABRA1 (0.61) SLC6A2SLC6A4SLC6A3SIGMAR1GABRA1
SCHEMBL8567596 0.71 GABRA1 (0.42) SIGMAR1GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238423-A9 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238423-A9 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS BCL2A1, BCL2L1, BCL3 KCNH2 2357/4885CHRM1 4745/4885CHRM2 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.